ACADIA Pharmaceuticals Inc.

Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to

Are you a current or former employee of the company?*YesNo


+Additional Purchases


+Additional Sales

If you prefer, you may submit your transaction information or comments/questions in the box below:

There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.

We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at, or by email at

If you choose to take no action, you can remain an absent class member.

Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.

The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Portnoy Law Firm
Lesley F. Portnoy, Esq.,
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067

On February 15, 2024, Culper Research released a critical analysis suggesting that ACADIA’s much-awaited drug for treating Ret Syndrome, Daybue, launched in April 2023, has failed to meet expectations. According to Culper, the drug has disappointed patients, caregivers, physicians, and insurers alike, with the initiation of new patient treatments peaking last summer. They argue that Daybue will generate revenues significantly lower than initial projections, and its underperformance will further strain ACADIA’s financial resources. Following the release of this report, ACADIA’s stock value dropped by $0.38, a 1.49% decrease, ending the day at $25.18 per share.